ALPHYN BIOLOGICS is developing breakthrough therapies to treat the world’s most challenging, severe, and common skin diseases. We are dedicated to improving the lives of millions of patients worldwide with first-in-class, Multi-Target Therapeutics® (MTT) that are expected to be safe, powerful, and more effectively attack disease.

Striving for the
First Complete
Atopic Dermatitis

Zabalafin hydrogel (AB-101a) is in development to uniquely solve the critical challenges associated with treating mild-to-moderate atopic dermatitis (AD), the most common form of eczema. Developed with our proprietary, multi-target Zabalafin Platform, zabalafin hydrogel is a steroid-free topical with the potential to offer the first complete therapeutic for AD, targeting the immune system and bacterial components of the disease, with a safety, side effect and patient tolerability profile ideally suited for long-term, worry-free continuous use.

Alphyn Lab Testing

A Phase 2a clinical trial evaluating zabalafin hydrogel in adults and children (age 2 and up) with AD, in 2 cohorts, with and without infected AD skin, met all primary and secondary endpoints, demonstrating significant and clinically relevant improvements in itch, quality of life, inflammation, elimination of infected AD skin and control of Staph bacteria- associated and other AD Flares. This clinical trial demonstrated minimal side effects and excellent patient tolerability.

Powered by the Zabalafin Platform for Multi-Target Therapeutics

Alphyn’s Zabalafin Platform (AB-101 Drug Platform) contains multiple bioactive compounds to power a new class of therapeutics capable of attacking disease in numerous ways. This unique approach and platform produce Multi-Target Therapeutics that target multiple diseases as well as multiple symptoms and causes of individual diseases.

Alphyn News